TY - JOUR
T1 - The TiLOOP® Male Sling
T2 - Did We Forejudge
AU - Debates On Male Incontinence (DOMINO)-Project 8
AU - Hüsch, Tanja
AU - Kretschmer, Alexander
AU - Thomsen, Frauke
AU - Kronlachner, Dominik
AU - Kurosch, Martin
AU - Obaje, Alice
AU - Anding, Ralf
AU - Kirschner-Hermanns, Ruth
AU - Pottek, Tobias
AU - Rose, Achim
AU - Olianas, Roberto
AU - Friedl, Alexander
AU - Hübner, Wilhelm
AU - Homberg, Roland
AU - Pfitzenmaier, Jesco
AU - Grein, Ulrich
AU - Queissert, Fabian
AU - Naumann, Carsten Maik
AU - Schweiger, Josef
AU - Wotzka, Carola
AU - Nyarangi-Dix, Joanne
AU - Brehmer, Bernhard
AU - Ulm, Kurt
AU - Bauer, Ricarda M.
AU - Haferkamp, Axel
N1 - Publisher Copyright:
© 2016 S. Karger AG, Basel. All rights reserved.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Introduction: To evaluate the safety and efficacy of the TiLOOP® male sling (pfm medical, Cologne, Germany) used in the treatment for male stress urinary incontinence (SUI). Material and Methods: We retrospectively evaluated a total of 34 patients with a TiLOOP® male sling. Perioperative complication rates were assessed and validated questionnaires were prospectively evaluated to assess quality of life and satisfaction rate. Outcome and complication rates were analysed by using descriptive statistics. Correlation of continence outcome and risk factors was performed with the chi-square test. A p value below 0.05 was considered statistically significant. Results: The majority of patients (70.6%) were diagnosed with mild or moderate male SUI. During surgery, one instance (2.9%) of intraoperative urethral injury was observed. There were no immediate postoperative complications. The mean follow-up time was 44.6 months. An improvement of male SUI was reported by 61.9% of the patients and 38.1% reported no change according the Patient Global Impression of Improvement. The mean perineal pain score was 0.5 according to the international index of pain. Conclusions: The TiLOOP® is a safe treatment option for male SUI in our cohort with a low complication rate. However, the functional outcome of the TiLOOP® was inferior when compared to the outcome of the AdVance® male sling.
AB - Introduction: To evaluate the safety and efficacy of the TiLOOP® male sling (pfm medical, Cologne, Germany) used in the treatment for male stress urinary incontinence (SUI). Material and Methods: We retrospectively evaluated a total of 34 patients with a TiLOOP® male sling. Perioperative complication rates were assessed and validated questionnaires were prospectively evaluated to assess quality of life and satisfaction rate. Outcome and complication rates were analysed by using descriptive statistics. Correlation of continence outcome and risk factors was performed with the chi-square test. A p value below 0.05 was considered statistically significant. Results: The majority of patients (70.6%) were diagnosed with mild or moderate male SUI. During surgery, one instance (2.9%) of intraoperative urethral injury was observed. There were no immediate postoperative complications. The mean follow-up time was 44.6 months. An improvement of male SUI was reported by 61.9% of the patients and 38.1% reported no change according the Patient Global Impression of Improvement. The mean perineal pain score was 0.5 according to the international index of pain. Conclusions: The TiLOOP® is a safe treatment option for male SUI in our cohort with a low complication rate. However, the functional outcome of the TiLOOP® was inferior when compared to the outcome of the AdVance® male sling.
KW - Male sling
KW - Male stress urinary incontinence
KW - Minimal-invasive alternatives
KW - TiLOOP
UR - http://www.scopus.com/inward/record.url?scp=85032348281&partnerID=8YFLogxK
U2 - 10.1159/000477765
DO - 10.1159/000477765
M3 - Article
C2 - 29069660
AN - SCOPUS:85032348281
SN - 0042-1138
VL - 100
SP - 216
EP - 221
JO - Urologia Internationalis
JF - Urologia Internationalis
IS - 2
ER -